Compare Crispr Therapeutics AG (CRSP) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Workiva Inc — how do they compare? Crispr Therapeutics AG trades at $52.75 (market cap $4.88B), while Workiva Inc trades at $73.6 (market cap $4.01B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap, and Workiva Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Workiva Inc for 21 Days on average.
| CRSP | WK | |
|---|---|---|
Market Cap | $4.88B | $4.01B |
Volume | 2,861,747 | 1,301,708 |
Sector | Health | Technology |
52-Week High | $74.92 | $93.31 |
52-Week Low | $44.34 | $44.31 |
Typical Hold Time | 77 Days | 21 Days |
Enterprise Value | $3.30B | $3.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
WK trades at $73.79, up 3.16% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $0.798. Revenue grew to $966 million in 2026, turning a net loss in 2025 into a $47 million profit. Analyst sentiment is overwhelmingly positive, with 16 buy ratings and a consensus price target of $86.
The outlook for WK is favorable, driven by consistent earnings outperformance and revenue growth, though high valuation multiples like a P/E of 87.73 pose risks. Key opportunities include AI-driven product innovations and inclusion in investment analyses, while risks involve competitive pressures and reliance on continued execution. The stock's proximity to its 52-week high suggests momentum but warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
